combination therapy

LIGHTHOUSE (OP-108): daratumumab monotherapy vs triplet therapy in R/R myeloma 2:32
LIGHTHOUSE (OP-108): daratumumab monotherapy vs triplet therapy in R/R myeloma
Maria-Victoria Mateos • 23 Jun 2021
Effect of lenalidomide-refractory status on safety and efficacy of XVd versus Vd in myeloma 3:26
Effect of lenalidomide-refractory status on safety and efficacy of XVd versus Vd in myeloma
Maria-Victoria Mateos • 23 Jun 2021
Update on iberdomide treatment combinations in R/R myeloma 2:52
Update on iberdomide treatment combinations in R/R myeloma
Niels van de Donk • 24 Jun 2021
Young myeloma: treatment algorithm 4:48
Young myeloma: treatment algorithm
Muzaffar Qazilbash • 12 May 2021
John Gribben’s ASH 2019 CLL and lymphoma highlights 4:10
John Gribben’s ASH 2019 CLL and lymphoma highlights
John Gribben
Promising venetoclax updates in AML: DEC10-VEN, CLAD/LDAC, antifungals 2:57
Promising venetoclax updates in AML: DEC10-VEN, CLAD/LDAC, antifungals
Marina Konopleva • 8 Dec 2019
Developing mantle cell lymphoma treatment for further success 1:33
Developing mantle cell lymphoma treatment for further success
John Kuruvilla
Update on selinexor for myeloma and large cell lymphomas 2:02
Update on selinexor for myeloma and large cell lymphomas
John Kuruvilla
MRD in the immuno-chemo era 0:51
MRD in the immuno-chemo era
Florence Cymbalista • 22 Sep 2019
MURANO: outcomes after the end of treatment 2:53
MURANO: outcomes after the end of treatment
John Seymour • 22 Sep 2019
CLL treatment: statistical analysis in predictive medicine 3:10
CLL treatment: statistical analysis in predictive medicine
Kevin Coombes • 22 Sep 2019
Comparing CLL regimens with MRD 2:41
Comparing CLL regimens with MRD
John Seymour • 22 Sep 2019
Predicting suboptimal response through intermediate MRD 3:48
Predicting suboptimal response through intermediate MRD
Andrew Rawstron • 22 Sep 2019
Novel combination therapies in CLL 1:44
Novel combination therapies in CLL
Matthew Davids • 22 Sep 2019
Will cellular therapy have a role in CLL in 2020? 2:32
Will cellular therapy have a role in CLL in 2020?
Anna Schuh • 22 Sep 2019
Venetoclax phase III trial disappointment 1:29
Venetoclax phase III trial disappointment
Lawrence Boise • 12 Sep 2019
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals